AU4714393A - Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity - Google Patents

Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity

Info

Publication number
AU4714393A
AU4714393A AU47143/93A AU4714393A AU4714393A AU 4714393 A AU4714393 A AU 4714393A AU 47143/93 A AU47143/93 A AU 47143/93A AU 4714393 A AU4714393 A AU 4714393A AU 4714393 A AU4714393 A AU 4714393A
Authority
AU
Australia
Prior art keywords
dicyclopropymethyl
xanthine
obesity
prevention
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47143/93A
Other languages
English (en)
Inventor
Kathryn Gay Ellis
Barbara Anne Spicer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU4714393A publication Critical patent/AU4714393A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU47143/93A 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity Abandoned AU4714393A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment
GB9215633 1992-07-23
PCT/GB1993/001539 WO1994002150A1 (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity

Publications (1)

Publication Number Publication Date
AU4714393A true AU4714393A (en) 1994-02-14

Family

ID=10719151

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47143/93A Abandoned AU4714393A (en) 1992-07-23 1993-07-21 Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity

Country Status (9)

Country Link
EP (1) EP0651642A1 (cs)
JP (1) JPH07509456A (cs)
CN (1) CN1043610C (cs)
AU (1) AU4714393A (cs)
GB (1) GB9215633D0 (cs)
MX (1) MX9304435A (cs)
TW (1) TW258663B (cs)
WO (1) WO1994002150A1 (cs)
ZA (1) ZA935339B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783408A (en) * 1995-06-07 1998-07-21 Hamilton; Bradford S. Method for screening potential anti-obesity agents
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1404675B1 (en) * 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
AU2002331311A1 (en) * 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP5091106B2 (ja) 2005-03-08 2012-12-05 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病の治療のためのロフルミラスト
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds

Also Published As

Publication number Publication date
WO1994002150A1 (en) 1994-02-03
CN1043610C (zh) 1999-06-16
JPH07509456A (ja) 1995-10-19
EP0651642A1 (en) 1995-05-10
GB9215633D0 (en) 1992-09-09
ZA935339B (en) 1995-01-18
CN1114880A (zh) 1996-01-17
TW258663B (cs) 1995-10-01
MX9304435A (es) 1994-04-29

Similar Documents

Publication Publication Date Title
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
AU7545594A (en) Implantable device for the treatment of aedemas
AU4620789A (en) Treatment of obesity
AU4050797A (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
GB9619331D0 (en) Selective ›3 agonists for the treatment of diabetes and obesity
AU6194094A (en) Sweetener, process for the preparation thereof and the use thereof
HK1007963B (en) Medicament containing triclosan for treating gastro-intestinal disorders
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP0648492A3 (en) Inhibition of phosphatidylinositol-3-kinase with viridin, dimethoxyviridin, viridiol, dimethoxyviridiol, virone, wortmannolone, and their derivatives.
AU6425496A (en) Treatment for juvenile diabetes
AU7772794A (en) Treatment of obesity
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
PH31323A (en) Alkali-treated bagasse and its preparation and use.
AU6801694A (en) The treatment of small animals
AU1924795A (en) Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration
AU6160594A (en) Diabetes prevention and treatment
AU4288293A (en) Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
AU4705193A (en) Medicaments for the treatment or prevention of elevated intraocular pressure
AU7761694A (en) Intrastromal photorefractive keratectomy
AU1405595A (en) Use of thalidomide for the treatment of non-insulin dependent diabetes mellitus
AU7978794A (en) 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
AU7384094A (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
EP0630383A4 (en) METHODS FOR TREATING DIABETIS.